Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy. (12th December 2013)

• Record Type: Journal Article
• Authors: Tsoukas, Christos; Gilbert, Louise; Lewis, Trevor; Hatzakis, George; Falcon, Ron; Mrus, Joseph
• Other Names: D'ettorre G. Academic Editor.; Petrovas C. Academic Editor.
• Is Part Of: ISRN AIDS. Volume 2013(2013)
• Publication Date: 2013-12-12
• Subjects: AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome; AIDS (Disease); Periodical; Electronic journals; Periodicals; 616.9792
• DOI: 10.1155/2013/358294
• Languages: English
• ISSNs: 2090-939X

Abstract

Abstract : Objective . During the course of HIV infection, progressive immune deficiency occurs. The aim of this prospective substudy was to evaluate the recovery of functional immunity in a subset of patients from the GRACE (Gender, Race, And Clinical Experience) study treated with a DRV/r-based regimen. Methods . The recovery of functional immunity with a darunavir/ritonavir-based regimen was assessed in a subset of treatment-experienced, HIV-1 infected patients from the GRACE study. Results . 19/32 patients (59%) enrolled in the substudy were virologically suppressed (<50 copies/mL). In these patients, median (range) CD4+ cell count increased from 222 (2, 398) cells/mm 3 at baseline to 398 (119, 812) cells/mm 3 at Week 48. CD8+% decreased significantly from baseline to Week 48 (P = .03 ). Proliferation of CD4+ lymphocytes in response to CD3+/CD28+, phytohemagglutinin, and pokeweed was significantly increased (P < .01 ) by Week 12. Proliferation in response to Candida and tetanus was significantly increased by Week 48 (P < .01 andP = .014, resp.). Staphylococcal enterotoxin B-stimulated tumor necrosis factor-alpha and interleukin-2 in CD4+ cells was significantly increased by Week 12 (P = .046 ) and Week 48 (P < .01 ), respectively. Conclusions . Darunavir/ritonavir-based therapy demonstrated improvements in CD4+ cell recovery and association with progressive functional immune recovery over 48 weeks. This trial is registered withNCT00381303 .